Verve Therapeutics (NASDAQ:VERV) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV) in a research note published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Other analysts also recently issued reports about the company. Royal Bank of Canada decreased their price target on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Six analysts have rated the stock with a buy rating, According to MarketBeat, Verve Therapeutics has an average rating of “Buy” and an average target price of $25.50.

Verve Therapeutics Price Performance

NASDAQ VERV opened at $5.84 on Tuesday. The company has a fifty day moving average price of $6.98 and a 200-day moving average price of $6.09. The firm has a market cap of $518.57 million, a price-to-earnings ratio of -2.37 and a beta of 1.77. Verve Therapeutics has a 1 year low of $4.31 and a 1 year high of $13.63.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The business had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. On average, research analysts anticipate that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Verve Therapeutics

Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after buying an additional 3,964 shares during the period. IFP Advisors Inc increased its holdings in Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after acquiring an additional 8,237 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Verve Therapeutics in the 4th quarter valued at about $50,000. Erste Asset Management GmbH bought a new position in Verve Therapeutics during the third quarter worth about $56,000. Finally, Impact Partnership Wealth LLC purchased a new position in shares of Verve Therapeutics in the fourth quarter worth about $70,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.